Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Receivables (2016 - 2025)

Historic Receivables for Traws Pharma (TRAW) over the last 12 years, with Q3 2025 value amounting to $2.0 million.

  • Traws Pharma's Receivables fell 612.92% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 612.92%. This contributed to the annual value of $1.8 million for FY2024, which is 970555.56% up from last year.
  • As of Q3 2025, Traws Pharma's Receivables stood at $2.0 million, which was down 612.92% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Receivables registered a high of $2.1 million during Q3 2024, and its lowest value of $17000.0 during Q1 2023.
  • In the last 5 years, Traws Pharma's Receivables had a median value of $28000.0 in 2021 and averaged $483894.7.
  • As far as peak fluctuations go, Traws Pharma's Receivables tumbled by 3928.57% in 2023, and later skyrocketed by 1168333.33% in 2024.
  • Over the past 5 years, Traws Pharma's Receivables (Quarter) stood at $28000.0 in 2021, then rose by 3.57% to $29000.0 in 2022, then plummeted by 37.93% to $18000.0 in 2023, then soared by 9705.56% to $1.8 million in 2024, then rose by 12.8% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.3 million for Q2 2025, and $1.7 million during Q1 2025.